Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Frontline tislelizumab for older patients with newly diagnosed classical Hodgkin lymphoma unsuitable for standard chemotherapy
2022-503090-11-00Phase 2Authorised
- Sponsor
- Fondazione Italiana Linfomi
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in classical Hodgkin lymphoma (cHL), sponsored by Fondazione Italiana Linfomi. Primary endpoint: Overall response rate. Planned start May 2024; status: authorised.
02
Drugs
tislelizumab
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on 2022-503090-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-503090-11-00.